NCT06551129Recruiting
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study
Source: ClinicalTrials.gov · Last updated 7 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 118 (estimated)
- First submitted
- 6 Aug 2024
- Start date
- 10 May 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06551129
What you commit to
- Study type: Observational
- Planned participants: 118
- From 10 May 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously or currently enrolled in clinical trials for any cardiac myosin inhibitors
- Enrolled in any clinical trials at the time of or within the six-month period prior to the screening
- Had heart attack requiring coronary artery bypass grafting within the three-month period prior to the screening
- Had stroke or transient ischemic attack within the six-month period prior to the screening
- Had major lung (thoracic) or heart (cardiac) surgery within the six-month period prior to the screening
- Hospitalized requiring an overnight stay at the time of or within the two-week period prior to the screening
Other illness
- Had moderate-to-severe lung disease which impacted the ability to perform daily activities of living and ability to breathe
- Scheduled for a major surgery for the next three months, such as joint surgeries including hip replacement, abdominal surgeries, lung surgeries, heart surgeries, eye surgeries, brain surgeries, and any other major surgeries that require general anesthesia and at least an overnight hospital stay
Other
- Treated for \>7 days with mavacamten by the day of completing the baseline survey
Who the study is looking for
- Participants ≥18 years of age.
- Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy
- Provided informed consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Analysis Group, Inc. Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.